Roger Paredes, MD, PhD

Department of Infectious Diseases
Hospital Universitari Germans Trias i Pujol
Principal Investigator
Microbial Genomics
Institut de Recerca de la SIDA – irsiCaixa
Associate Editor
Journal of Infectious Diseases
Adjunct Associate Professor
Department of Pathology
School of Medicine
Center for Global Health and Diseases
School of Medicine

Research Information

Research Interests

Roger Paredes, MD, PhD, is Head of the Infectious Diseases Department, Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. He obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialized in HIV research at the Brigham & Women’s Hospital, Harvard Medical School, through a La Caixa grant for postgraduate studies. His team at irsiCaixa has contributed to define the clinical utility of HIV-1 deep sequencing in high- and low-income countries. His lab is now leading pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. They were the first to describe a link between sexual practices and the fecal microbiome composition. Dr. Paredes coordinates the 10 million-euro Horizon 2020 EU grant MISTRAL (GA-847943) and is co-PI in 3 grants from the Canadian Institutes of Health Research aimed at disentangling the role of the human microbiome on HIV pathogenesis, transmission, vaccine response and associated cancers. During the COVID-19 pandemic, Dr Paredes has been the Spanish National Coordinator of seminal NIH/NIAID-funded randomized clinical trials on COVID-19 therapeutics, including ACTT-1 and 2 and the ACTIV-3/TICO and STRIVE platforms, which have defined the current standard of care for this disease in hospitalized patients as well as in outpatients. His department hosts the largest Long COVID unit in Spain, which follows >2000 subjects. Dr. Paredes is member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee, the WHO HIV treatment guidelines group, and the WHO Clinical Network on COVID-19. He is coauthor of the Spanish HIV (GESIDA) and COVID-19 (SEIMC) treatment guidelines and is member of the IAS-USA HIV Drug resistance group. He is Adjunct Associate Professor of the Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, and Associate Editor of the prestigious Journal of Infectious Diseases.